EIKN’s (EIKN) Underperform Rating Reiterated at Wedbush

Wedbush restated their underperform rating on shares of EIKN (NASDAQ:EIKN) in a research note issued to investors on Tuesday morning,Benzinga reports. Wedbush currently has a $7.00 price objective on the stock.

EIKN has been the topic of a number of other research reports. Wall Street Zen upgraded shares of EIKN from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Morgan Stanley began coverage on EIKN in a research report on Monday, March 2nd. They issued an “overweight” rating and a $32.00 target price on the stock. Bank of America began coverage on EIKN in a report on Monday, March 2nd. They issued a “buy” rating and a $34.00 target price on the stock. Cantor Fitzgerald assumed coverage on EIKN in a research report on Monday, March 2nd. They set an “overweight” rating for the company. Finally, JPMorgan Chase & Co. initiated coverage on EIKN in a research note on Monday, March 2nd. They set an “overweight” rating and a $29.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, EIKN currently has an average rating of “Moderate Buy” and a consensus price target of $25.60.

EIKN Price Performance

EIKN stock opened at $9.90 on Tuesday. EIKN has a 1 year low of $9.46 and a 1 year high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.